Biotechbedrijf Galapagos plaatst 2 miljoen nieuwe aandelen
- KAPITAAL VOOR VERSNELLING ONTWIKKELING VAN NIEUWE MEDICIJNEN
17-10-2009 - Groefinanciering
Galapagos NV (Euronext: GLPG) today announces its intention to issue up to 2,125,925 new ordinary shares. Fortis Bank Nederland - MeesPierson Corporate Finance & Capital Markets will be acting as Sole Global Coordinator and Sole Bookrunner for the offering.
The Board of Directors of Galapagos will proceed to the issuance of up to 2,125,925 new ordinary shares under the authorized capital. The new shares will be offered through an accelerated bookbuild offering to eligible institutional and other qualified investors, and will be admitted to listing on NYSE Euronext Brussels following their issuance. The offering will start Friday 16 October 2009 at 8:00 am CET.
?Galapagos is well on track to achieve its 2009 operational and financial objectives, with three programs in the clinic and ?100 million in revenues,? said Onno van de Stolpe, Chief Executive Officer of Galapagos. ?The proceeds of this capital increase will be used to accelerate the clinical development of our candidate medicines, including next year's Phase II clinical trial of GLPG0259 for rheumatoid arthritis.?